12 results about "Spermatogenesis" patented technology

The application discloses a seminal plasma metabolic biomarker combination for male infertility spermatogenesis obstacle typing diagnosis, and relates to the field of biological science and technology.The application records the metabolic fingerprints of 475 seminal plasma samples by means of nanoparticle-enhanced laser desorption / ionization mass spectrometry, and constructs a seminal plasma metabolic fingerprint database related to spermatogenesis obstacle (SPGF). Then, through machine learning and statistical analysis, six metabolic biomarkers for SPGF typing diagnosis are screened and identified in the seminal plasma, and the six metabolic biomarkers can realize accurate typing of SPGF (AUC=0.814). The application has the advantages of simple sample pretreatment, fast analysis speed and low cost by means of recording the metabolic fingerprints of seminal plasma by means of nanoparticle-enhanced laser desorption / ionization mass spectrometry. Through the synthesized iron oxide nanoparticles as a matrix, small molecule metabolites in the seminal plasma can be efficiently captured and ionized, and complex pretreatment steps such as deproteinization and chromatographic separation are not needed, so that super-fast analysis, super-high sensitivity, extremely low sample consumption and excellent repeatability detection are realized.

The invention provides a method for inducing feminization of chlamys farreri through miRNA (micro Ribonucleic Acid), which is used for realizing sex control of conversion from male to female by reducing the expression quantity of DMRT1 gene in gonad of chlamys farreri. According to the method, miRNA, miRNA mimics or miRNA Agomir which can be used for reducing the expression quantity of the DMRT1 gene is injected. Wherein the sequence of the miRNA is SEQ ID NO: 1. The miRNA disclosed by the invention can target a male sex differentiation gene DMRT1 and down-regulate the expression of the male sex differentiation gene DMRT1, mediate the male sex differentiation gene DMRT1 to participate in spermatogenesis and testis function maintenance, and realize female transformation of a male individual; according to the invention, the miRNA overexpression technology is utilized for functional verification in shellfish for the first time, and a technical platform is established for functional research of miRNAs.

The invention provides a pyrrolidone tricyclic compound and a preparation method thereof, and application of the pyrrolidone tricyclic compound in preparation of drugs for treating neurodegenerative diseases, especially antidepressant drugs. The structural formula of the pyrrolidone tricyclic compound is as shown in general formulas A and 13. Experimental studies on in-vitro PC12 cell injury protection activity, in-vivo mouse anti-depression activity, hERG potassium channel inhibition and mouse head shaking show that the compound disclosed by the invention can be used for preparing neurodegenerative diseases, especially quickly-acting anti-depression drugs, and has the remarkable advantage of improving the spermatogenesis function.

The invention relates to the technical field of animal breeding, in particular to a boar semen improved feed additive based on a herba epimedii compound as well as a preparation method and application of the boar semen improved feed additive. The improved feed additive is prepared from the following active ingredients in parts by weight: 15 to 35 parts of herba epimedii extract, 10 to 25 parts of radix salviae miltiorrhizae extract, 8 to 20 parts of radix rehmanniae extract, 5 to 15 parts of caulis sinomenii extract, 0.1 to 0.8 part of vitamin E and 0.05 to 0.2 part of organic zinc. According to the invention, multiple active ingredients such as the herba epimedii extract, the organic zinc, the radix salviae miltiorrhizae, the radix rehmanniae and the caulis sinomenii are systematically matched with a preferred carrier, so that multi-path synergy in the aspects of spermatogenesis promotion, oxidation resistance, inflammation resistance, endocrine regulation, preparation delivery and the like is realized, and the semen quality of boars is remarkably improved.

The invention relates to an oral dosage unit for use in a method of contraception in a human male, said oral dosage units containing GnRH antagonist and dehydroepiandrosterone (DHEA), the method comprising once daily oral administration of the oral dosage unit to the human male during a period of at least 7 days. This contraceptive method is convenient, effectively suppresses spermatogenesis and is reversible. Another aspect of the invention relates to a dosage unit comprising: • GnRH antagonist selected from: o 50-250 mg relugolix; o 167-833 mg linzagolix; o 113-583 mg elagolix; • 100-800 mg dehydroepiandrosterone.

The application discloses a construction method of a paternal cognitive and affective disorder animal model and application thereof. The paternal cognitive and affective disorder animal model is constructed by daily intragastric perfusion of caffeine (60 mg / kg.d) to male rats at the age of 6 weeks, and the administration is continued for 8 weeks to cover a complete spermatogenesis cycle, so that a paternal pre-pregnancy caffeine exposure model is constructed. The offspring is weaned and separated into cages at the age of 4 weeks, and typical cognitive and affective behavior abnormalities of the male and female offspring appear at the age of 12 weeks and 28 weeks. Based on the paternal cognitive and affective disorder animal model, it is found that the pre-pregnancy caffeine exposure (PPCE) can cause inhibition of hippocampal neural stem cell differentiation of the offspring. The animal model constructed by the application is novel, reliable and simple, and has important significance for elucidating the occurrence mechanism of the paternal cognitive and affective disorder, and exploring early warning and intervention targets.

The invention relates to the field of fertility preservation and protection before adolescence, in particular to a transition culture method before immature testicular tissue transplantation. In a transition culture process before immature testicular tissue transplantation, coexistence states (such as FSH and testosterone continuously exist in a male body) of various growth factors and hormones in an in-vivo microenvironment are simulated, or in-vivo physiological dynamic changes are simulated. According to the transition culture method disclosed by the invention, the huge environmental difference caused by transplanting the testicular tissue before adolescence to the mature testicular tissue is reduced, the proliferation of spermatogonium and the maturation of supporting cells are remarkably promoted, the survival rate of the spermatogonium after transplantation is improved, and a foundation is laid for spermatogenesis after transplantation.

The invention belongs to the technical field of aquatic organisms, and particularly relates to dsRNA interference primers for regulating a sex gene Dmrta2 of blue crabs as well as a method and application of the dsRNA interference primers. The invention provides dsRNA (double-stranded ribonucleic acid) for regulating and controlling a sex gene of blue crab Dmrta2. The dsRNA is obtained by taking a spliceosome sequence as a template through in-vitro transcription; the invention also provides an RNA interference method for regulating and controlling testis development of scylla paramamosain by using the Dmrta2 gene variable spliceosome. The method comprises in-vivo interference treatment and in-vitro interference treatment. The result of the embodiment shows that the RNA interference is implemented in the in-vivo and in-vitro tissue culture of the scylla paramamosain by the method, the expression interference of the Dmrta2 gene variable spliceosome can be successfully completed, and the retardation or abnormality of sperm generation and the tissue change of sperm cavity after the interference of the Dmrta2 gene variable spliceosome can be successfully observed.

The present invention provides methods for diagnosing or predicting a fertility defect, such as infertility, in a mammalian or human male subject by detecting PPP6R3 or a combination of PPP6R3, EIF3C and EIF4G1. The invention also provides kits and instruments for diagnosing or predicting fertility defects, such as infertility disorders, in mammalian male individuals by detecting said proteins. According to the application, it is found and proved that PPP6R3 is crucial to spermatogenesis for the first time, S39 of EIF3C and S1217 of EIF4G1 are targets for PP6 to regulate spermatogonial differentiation, a new insight is provided for the relation between phosphorylation participated by phosphoprotein phosphatase and spermatogonial differentiation, and deep research on the relation is beneficial to development of a male infertility treatment method.

The invention is applicable to the technical field of biological medicine, and provides a resveratrol carbon dot-loaded cell membrane bionic nano-vesicle and application thereof, and the resveratrol carbon dot-loaded cell membrane bionic nano-vesicle is prepared by the following preparation process: mixing pure trans-resveratrol with ultrapure water, adjusting the pH value until complete dissolution, reacting the solution to obtain a carbon dot solution, centrifuging, filtering with a filter membrane, dialyzing and purifying to obtain the resveratrol carbon dot-loaded cell membrane bionic nano-vesicle. Carrying out rotary evaporation and freeze-drying to obtain RES CDs; and dropwise adding Cy7 into the DSPE-PEG solution, stirring overnight, dialyzing to remove free Cy7 to obtain Cy7-coated PEG, and mixing TM4-M, RES CDs and Cy7-coated PEG to obtain the resveratrol carbon dot-loaded cell membrane bionic nano-vesicles RCD-coated PCy-coated EVs. The invention also discloses a preparation method of the resveratrol carbon dot-loaded cell membrane bionic nano-vesicles RCD-coated PCy-coated EVs and application of the resveratrol carbon dot-loaded cell membrane bionic nano-vesicles. The vesicles based on the supporting cell membrane prepared by the invention can specifically deliver the resveratrol carbon dots to the blood testis barrier and treat spermatogenesis disorder.

The invention belongs to the technical field of reproductive health, and particularly relates to a new application of testis metabolite 2-propyl thiazolidine-4-carboxylic acid (2-n-propyylthiazolidine-4-carboxylic acid, PTCA), an application of the 2-propyl thiazolidine-4-carboxylic acid in preparation of a medicine for treating testis dyszoospermia induced by AFB1, the PTCA can promote testis interstitial cell testosterone secretion, and the medicine for treating testis dyszoospermia induced by AFB1 can be used for treating testis dyszoospermia induced by AFB1, so that the testis dyszoospermia induced by AFB1 can be used for treating testis dyszoospermia induced by AFB1. The PI3K / AKT / NRF2 antioxidant signal channel in the testis tissue is activated, the testis injury induced by AFB1 is relieved, and the ROS level in the testis tissue is reduced; according to the application, the important effect of PTCA as a novel testis metabolism marker and protective agent in the male reproductive system is disclosed for the first time, a new insight is provided for understanding the reproductive toxicity mechanism of AFB1, and an experimental foundation is laid for an intervention strategy of metabolite applied to male dyszoospermia.

The invention provides a spermatogenic function multi-dimensional evaluation method and system, and the method comprises the steps: obtaining abnormal parameters from spermatogenic problem positioning, determining the deviation degree through comparison with a preset normal range, and obtaining a male evaluation score; if the type is female, extracting an ovarian reserve mark from the preliminary classification result, processing reserve parameters by adopting a support vector machine model, judging a reserve level, and obtaining reserve problem positioning; obtaining a level index from reserve problem positioning, determining a reserve deviation by calculating a difference with a preset reference, and obtaining a female evaluation score; integrating the deviation data from the male assessment score or the female assessment score, generating a comprehensive feedback report by adopting a fusion algorithm, and determining an overall fertility level; and grade information is extracted from the comprehensive feedback report, a clinical result is generated through a rapid output module, and a final evaluation conclusion is obtained.